Which Has The Stamina To Keep Climbing? SABMiller Plc (SBMRY), Imageware Systems Inc (IWSY) and IGI Laboratories Inc (IG)

Posted by admin April 30, 2015 0 Comment 744 views


New York, NY – GDP INSIDER  –  04/30/2014.

This article discusses three companies: SABMiller Plc (ADR) (OTCMKTS:SBMRY), Imageware Systems Inc (OTCMKTS:IWSY) and IGI Laboratories Inc (NYSEMKT:IG)

SABMiller Plc (ADR) (OTCMKTS:SBMRY) declined yesterday with the stock declining 1.45% or $0.79 to close at $53.63 on light trading of 0.082 million shares, compared to its three month average trading volume of 0.118 million. The manufacturer and distributor of beer and other beverages has been trading within a narrow range of $52.25 and $54.42 since the beginning of the month and has been outperforming the S&P 500 so far this year, up 4.01% compared to the index, which has only gained 2.33% over the same period making it a hold.

Will SABMiller Plc Break Out Of Its Narrow Trading Range? Click Here For Free SBMRY Analysis.

Imageware Systems Inc (OTCMKTS:IWSY) climbed slightly yesterday after its recent falls with the stock closing up 0.55% or $0.01 to close the day at $1.82 on low trading of 0.047 million shares compared to its three month average trading volume of 0.135 million. The mobile and cloud based identity management solution provider has been climbing for most of the last one month with the stock gaining 7.69% compared to the S&P 500 index, which has gained only 0.99% over the same period. With quarterly revenue growth of 33.50% year on year and RSI of 52.15 the stock is starting to look like a good medium term buy.

Do Imageware Systems Fundamentals Support A Medium Term Investment? Delve Into The Details With Free IWSY Analysis.

IGI Laboratories Inc (NYSEMKT:IG) plummeted yesterday with the stock closing down 34.59% or $2.75 to finish the day at a new closing price of $5.20 on much higher than average trading volume of 12.204 million, compared to its three month average trading volume of 0.993 million. The developer and manufacturer of generic topical pharmaceutical products began to drop after analysts at Oppenheimer downgraded their rating on the stock from ‘outperform’ to ‘perform’. However, with strong quarterly revenue growth of 104.50% and RSI of 20.82, the stock has plenty of upside potential, making it a buy.

Should You Invest In IGI Laboratories Inc Now? Read Our Free IG Analysis To Know More.

About Ultimate Stock Alerts

UltimateStockAlerts.com covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit www.UltimateStockAlerts.com

Disclosure:  UltimateStockAlerts.com is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.


Write Your Comment